AF
TRDA icon

Allworth Financial’s Entrada Therapeutics TRDA Stock Holding History

Allworth Financial’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.9K Buy
+309
New +$3.54K ﹤0.01% 4096
2025
Q3 		– Sell
-62
Closed -$417 – 5047
2025
Q2 		$417 Buy
62
+26
+72% +$209 ﹤0.01% 4182
2025
Q1 		$323 Buy
+36
New +$449 ﹤0.01% 3782

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allworth Financial's TRDA Position: Q1 2026 in Review

Allworth Financial opened a new position in Entrada Therapeutics (TRDA) in Q1 2026: 309 shares worth $3.9K. The stake represents ﹤0.01% of the portfolio and ranks #4096 among its holdings. This is a return to the name: Allworth Financial previously reported a position in TRDA as recently as Q2 2025.

Allworth Financial first reported a position in TRDA in Q1 2025 and has held it in 3 quarters since. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Allworth Financial held 309 shares of Entrada Therapeutics worth $3.9K as of Q1 2026.
  • Entrada Therapeutics was a new Allworth Financial position in Q1 2026.
  • Entrada Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4096 holding.
  • Allworth Financial first reported a position in Entrada Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.